Cardiac Rhythm Management (MicroPort® CRM)
For more information Email: [email protected]

​MicroPort® CRM - redefining Pacing and ICD Therapy

Alizea™- The world’s smallest dual chamber pacemaker (1), the world's first AutoMRI™ technology to automatically adjust pacemaker settings for MRI scans (2), and the world’s first MR conditional mixed system (3).

Talentia™- The world’s longest-lasting implantable defibrillator (4) which embeds PARAD+™ a clinically proven arrhythmia discrimination algorithm providing the lowest rate of inappropriate shocks ever reported in medical literature (5).

Talentia™ CRT-D - The world’s longest-lasting cardiac resynchronization therapy defibrillators (6) and SonR™, the world’s first and only AV/VV optimization algorithm based on cardiac contractility leading to a 35% risk reduction of HF hospitalization (7).

References (See below)

Talentia™ SonR® CRT-D

Talentia™ICD

TALENTIA™ 4LV SONR® CRT-D

Automatic CRT Optimisation (9-10)
​
Being the longest-lasting 1.5 and 3T full body MRI-conditional CRT-D (4), and featuring BlueTooth Low Energya (BLE) connectivity Talentia™ 4LV SonR® defibrillators represents MicroPort® CRM's latest development in the field of cardiac care and heart failure management. Thanks to the SonR®technology, the world's only automatic CRT algorithm that is based on cardiac contractility, Talentia™ 4LV SonR® can provide continuous and advanced CRT optimization, improving the clinical outcomes (1,2).
AUTOMRI™ adaptive intelligence allows Talentia™ SonR® to automatically adapt to the MRI scanning environment, enabling essential therapies to provide a safe MRI pathway for your patients (6).
Features
  • BlueTooth Low Energy (BLE) connectivity – offers a high-quality connection for a seamless experience.
  • Outstanding longevity (4) – Protects patients from consequences of avoidable device replacement (5).
  • AUTOMRI™ – Provides the most appropriate therapy for as long as possible (6).
  • SonR™– Reduces the risk of heart failure hospitalization by 35% thanks to a CRT optimization automatically tailored to each patient’s need (9-10)
  • PARAD+™ including the Long Cycle Search – Achieves the lowest rate of inappropriate shocks ever reported in the literature (2,3).
  • Lead Parameter Evaluation (LPE) – Enhances patient’s protection through earlier lead failure detection and alert.
  • BTO™ – Brady Tachy Overlap. Supports patient exercise and detects slow ventricular tachycardia simultaneously.
  • WARAD™ – Window of Atrial Rate Acceleration Detection. Accurately detects AF even in case of undersensing using a dynamic atrial window (3).
  • Multipoint Pacing™ – Captures a broader area of the left ventricle (4).
  • Remote monitoring with SmartView™ Connect – Offers advanced patient monitoring and follow-up, providing timely alerts and detailed reports.
This product is not available for sale or distribution in the USA. For further information on product availability, please contact your local representative.

​References (See below)

TALENTIA™ ICD

World's Greatest projected Longevity (4)
​
The new Talentia™ defibrillators represent MicroPort® CRM's latest development in the field of cardiac care.
In addition to the advanced protection against sudden cardiac death, improving patients' quality of life (1,2,3). Talentia offers a Bluetooth Low Energy (BLE) connection for a seamless connectivity. Moreover, the world's greatest projected longevity (4) protects your patients from complications associated with infections and replacements (5).
AUTOMRI™ adaptive intelligence allows Talentia™ to automatically adapt to the MRI scanning environment, enabling essential therapies to provide a safe MRI pathway for your patients (6).
Features
  • BlueTooth Low Energy (BLE) connectivity – offers a high-quality connection for a seamless experience.
  • Outstanding longevity (4) – Protects patients from consequences of avoidable device replacement (5).
  • AUTOMRI™ – Provides the most appropriate therapy for as long as possible.
  • PARAD+™ including the Long Cycle Search – Achieves the lowest rate of inappropriate shocks ever reported in the literature (2,3).
  • Lead Parameter Evaluation (LPE) – Enhances patient’s protection through earlier lead failure detection and alert.
  • BTO™ – Brady Tachy Overlap. Supports patient exercise and detects slow ventricular tachycardia simultaneously.
  • SafeR™ – Lowers the risk of atrial fibrillation and hospitalization associated with the RV overstimulation1.
  • WARAD™ – Window of Atrial Rate Acceleration Detection. Accurately detects AF even in case of undersensing using a dynamic atrial window (2).
  • Remote Monitoring With Smartview™ Connect – Offers advanced patient monitoring and follow-up, providing timely alerts and detailed reports.
This product is not available for sale or distribution in the USA. For further information on product availability, please contact your local representative.

​References (See below)

Alizea™ 

​




​ALIZEA™ PM (LBBAP)

With Sleep Apnea Monitoring
​
Maintain excellent clinical follow-ups-remotely. Excellent longevity* in remote mode reduces the need for replacements (5). Efficiently manage AF while improving clinical outcomes.
Features
  • 13 years longevity with remote monitoring and full feature set ON*
  • LBBAP™ ​ – Able to provide Left Bundle Branch Area Pacing ensuring physiological pacing (6)
  • SafeR™ – Minimize ventricular pacing for SND and AVB patients (3,4).
  • World’s first MR conditional mixed system7** –  Expand MRI accessibility while maintaining the highest standards of safety, flexibility, and innovation
  • AUTOMRI™ – Making MRI scans easy and safe for pacemaker patients
  • Dual Sensor – Designed to physiologically modulate heart rhythm by combining accelerometer and minute ventilation sensors
  • Sleep Apnea Monitoring** – Screen and Monitor for Sleep Apnea
  • Bluetooth® Remote monitoring - Offer advanced patient monitoring and follow-up, providing timely alerts and detailed reports of your patient
*13 years with SafeR™ mode, assuming 5% V pacing and 50% A pacing, 60 min-1, 2.5 V, 0.35 ms, 750 Ohms, Holter ON, sensors ON, Remote ON
​
**Not available in the USA

References (See below)
More info
​References

General
  1. Transvenous pacemaker. Competition comparison across transvenous pacing systems made as of March 2025, refer to manufacturers manuals available online.
  2. MicroPort® CRM MRI Solutions Manuals available online at microportmanuals.com
  3. System consisting of a pacemaker and one or more lead(s). Refer to MRI solutions for complete information available online at microportmanuals.com
  4. Competition comparison made as of March 2020, refer to manufacturers manuals and Boston Scientific longevity calculator available online.
  5. Ruiz-Granell R, Dovellini EV, Dompnier A, et al. Algorithm-based reduction of inappropriate defibrillator shock: Results of the Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination-Implantable Cardioverter Defibrillator Study. Heart Rhythm. 2019 Sep;16(9):1429-1435.
  6. Competition comparison made as of March 2020, refer to manufacturers manuals and Boston Scientific longevity calculator available online.
  7. Brugada J, Delnoy PP, Brachmann J, et al. Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. Eur Heart J. 2017 Mar 7;38(10):730-738
TALENTIA™ 4LV SONR® REFERENCES
  1. Hofer D, Steffel J, Hürlimann D et al. Long-term incidence of inappropriate shocks in patients with implantable cardioverter defibrillators in clinical practice—an underestimated complication?. J Interv Card Electrophysiol 50, 219–226 (2017).
  2. Ruiz-Granell R, Dovellini EV, Dompnier A, Khalighi K, García-Campo E, Olivier A, Barcelo A, Ritter P. Algorithm-based reduction of inappropriate defibrillator shock: Results of the Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination-Implantable Cardioverter Defibrillator Study. Heart Rhythm. 2019 Sep;16(9):1429-1435
  3. Wolfgang Dichtl, et al. Low rates of inappropriate shocks in contemporary real-world implantable cardioverter defibrillator patients: the CARAT observational study, EP Europace, Volume 25, Issue 9, September 2023, euad186
  4. Competition comparison made as of March 2023, refer to manufacturers manuals and Boston Scientific longevity calculator available online
  5. Borleffs CJ, Thijssen J, de Bie MK, et al. Recurrent implantable cardioverter defibrillator replacement is associated with an increasing risk of pocket-related complications. Pacing Clin Electrophysiol. 2010 Aug;33(8):1013-1019.
  6. MicroPort® CRM MRI Solutions Manuals available online at microportmanuals.com
  7. Kolb et al. Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. JACC Heart Fail. 2014;2(6):611-619.
  8. Bonnet JL, Brusseau E, Limousin M, et al. Mode switch despite undersensing of atrial fibrillation in DDD pacing. Pacing Clin Electrophysiol. 1996 Nov;19(11 Pt 2):1724-8.
  9. Brugada J, Delnoy PP, Brachmann J, et al. Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. Eur Heart J. 2017 Mar 7;38(10):730-738
  10. Lunati M, Magenta G, Cattafi G, et al. Clinical Relevance Of Systematic CRT Device Optimization. J Atr Fibrillation. 2014 Aug 31;7(2):1077.
  11. Bonnet JL, Brusseau E, Limousin M, et al. Mode switch despite undersensing of atrial fibrillation in DDD pacing. Pacing Clin Electrophysiol. 1996 Nov;19(11 Pt 2):1724-8.
  12. Menardi E, Ballari GP, Goletto C, et al. Characterization ventricular activation pattern and hemodynamics during multipoint ventricular pacing. Heart Rhythm. Aug;12(8):1762-9.
TALENTIA™ REFERENCES
  1. Hofer D, Steffel J, Hürlimann D et al. Long-term incidence of inappropriate shocks in patients with implantable cardioverter defibrillators in clinical practice—an underestimated complication?. J Interv Card Electrophysiol 50, 219–226 (2017).
  2. Ruiz-Granell R, Dovellini EV, Dompnier A, Khalighi K, García-Campo E, Olivier A, Barcelo A, Ritter P. Algorithm-based reduction of inappropriate defibrillator shock: Results of the Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination-Implantable Cardioverter Defibrillator Study. Heart Rhythm. 2019 Sep;16(9):1429-1435
  3. Wolfgang Dichtl, et al. Low rates of inappropriate shocks in contemporary real-world implantable cardioverter defibrillator patients: the CARAT observational study, EP Europace, Volume 25, Issue 9, September 2023, euad186
  4. Competition comparison made as of March 2023, refer to manufacturers manuals and Boston Scientific longevity calculator available online
  5. Borleffs CJ, Thijssen J, de Bie MK, et al. Recurrent implantable cardioverter defibrillator replacement is associated with an increasing risk of pocket-related complications. Pacing Clin Electrophysiol. 2010 Aug;33(8):1013-1019.
  6. MicroPort® CRM MRI Solutions Manuals available online at microportmanuals.com

ALIZEA™  REFERENCES
  1. Competition comparison across transvenous pacing systems made as of September 2020, refer to manufacturers manuals available online
  2. MicroPort® MRI Solutions available at microportmanuals.com
  3. Stockburger M, et al. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity-a substudy of the ANSWER trial. Europace 2016;18:739–46.
  4. Stockburger M, et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in general population (ANSWER study). Eur Heart J. 2015;36:151–57
  5. Boriani G, Bertini M, Saporito D, et al. Impact of pacemaker longevity on expected device replacement rates: Results from computer simulations based on a multicenter registry (ESSENTIAL). Clin Cardiol. 2018;41(9):1185‐1191. doi:10.1002/clc.23003
  6. Alizea™ User Manual available online at microportmanuals.com
  7. System consisting of a pacemaker and one or more lead(s). Refer to MRI solutions for complete information available online at microportmanuals.com